Best Practices on Addressing Disparities and Practicing Multicultural Care in Myeloma



  1. AACR Cancer Disparities Progress Report 2022: Achieving the Bold Vision of Health Equity for Racial and Ethnic Minorities and Other Underserved Populations. American Association for Cancer Research. 2022. Accessed October 11, 2022.
  2. An update on cancer deaths in the United States. Centers for Disease Control and Prevention. Updated February 28, 2022. Accessed October 12, 2022.
  3. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417-435. doi:10.1007/s10552-008-9256-0
  4. Moss JL, Pinto CN, Srinivasan S, Cronin KA, Croyle RT. Persistent poverty and cancer mortality rates: an analysis of county-level poverty designations. Cancer Epidemiol Biomarkers Prev. 2020;29(10):1949-1954. doi:10.1158/1055-9965.EPI-20-0007
  5. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute; Surveillance, Epidemiology, and End Results Program. Updated April 9, 2020. Accessed October 10, 2022.
  6. Ailawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158(1):91-98. doi:10.1111/j.1365-2141.2012.09124.x
  7. Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved. 2010;21(3):879-97. doi:10.1353/hpu.0.0323.
  8. Brown EA, Bekker HL, Davison SN, Koffman J, Schell JO. Supportive care: communication strategies to improve cultural competence in shared decision making. Clin J Am Soc Nephrol. 2016;11(10):1902-1908. doi:10.2215/CJN.13661215
  9. Jayakrishnan TT, Bakalov V, Chahine Z, Lister J, Wegner RE, Sadashiv S. Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2021;14(3):218-230. doi:10.1016/j.hemonc.2020.09.005
  10. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum pretium--the just price. J Clin Oncol. 2013;31(28):3600-3604. doi:10.1200/JCO.2013.49.1845
  11. Dixit N, Rugo H, Burke NJ. Navigating a path to equity in cancer care: the role of patient navigation. Am Soc Clin Oncol Educ Book. 2021;41:1-8. doi:10.1200/EDBK_100026
  12. Creamer J, Shrider EA, Burns K, Chen F. Poverty in the United States: 2021. US Census Bureau. September 2022. Accessed October 12, 2022.
  13. Fiala MA, Wildes TM, Vij R. Racial disparities in the utilization of novel agents for frontline treatment of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(10):647-651. doi:10.1016/j.clml.2020.04.018
  14. Joshi H, Lin S, Fei K, et al. Multiple myeloma, race, insurance and treatment. Cancer Epidemiol. 2021;73:101974. doi:10.1016/j.canep.2021.101974
  15. Hu B, Boselli D, Pye LM, et al. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma. Cancer. 2021;127(21):3991-3997. doi:10.1002/cncr.33779
  16. Rocque GB, Pisu M, Jackson BE, et al; Patient Care Connect Group. Resource use and Medicare costs during lay navigation for geriatric patients with cancer. JAMA Oncol. 2017;3(6):817-825. doi:10.1001/jamaoncol.2016.6307
  17. Roland KB, Milliken EL, Rohan EA, et al. Use of community health workers and patient navigators to improve cancer outcomes among patients served by federally qualified health centers: a systematic literature review. Health Equity. 2017;1(1):61-76. doi:10.1089/heq.2017.0001
  18. DeSalvo JM, Young GS, Krok-Schoen JL, Paskett ED. Characterizing time to diagnostic resolution after an abnormal cancer screening exam in older adult participants in the Ohio Patient Navigation Research Program. J Aging Health. 2018;30(8):1284-1304. doi:10.1177/0898264317715184
  19. Awidi M, Al Hadidi S. Participation of black Americans in cancer clinical trials: current challenges and proposed solutions. JCO Oncol Pract. 2021;17(5):265-271. doi:10.1200/OP.21.00001
  20. Saxton C, Cutforth A, Gonzalo B, Nichosl H, Fearnley K. Understanding barriers and facilitators to clinical trial participation among Black patients with multiple myeloma. J Clin Oncol. 2022;40(16):12137. doi:10.1200/JCO.2022.40.16_suppl.12137
  21. Saxton C, Cutforth A, Gonzalo B, et al. Understanding barriers and facilitators to clinical trial participation among Black patients with multiple myeloma. J Clin Oncol. 2022;40(suppl 16):12137. doi:10.1200/JCO.2022.40.16_suppl.12137
  22. Bhatnagar V, Gormley N, Kazandjian D, et al. FDA analysis of racial demographics in multiple myeloma trials. Blood. 2017;130(suppl 1):4352. doi:10.1182/blood.V130.Suppl_1.4352.4352
  23. Gormley N, Fashoyin-Aje L, Locke T, et al. Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov. 2021;2(2):119-124. doi:10.1158/2643-3230.BCD-20-0123
  24. Kanapuru B, Fernandes LL, Fashoyin-Aje LA, et al. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Adv. 2022;6(6):1684-1691. doi:10.1182/bloodadvances.2021005482
  25. Quick facts. US Census Bureau. Accessed October 12, 2022.
Related Videos
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD